EVOLUS, INC. Research and Development in Process
EVOLUS, INC. (EOLS) reported Research and Development in Process of $2.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-08
- EVOLUS, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- EVOLUS, INC. research and development in process for the quarter ending 2022-09-30 was $0.00.
- EVOLUS, INC. research and development in process for the quarter ending 2022-06-30 was $2.00M.
- EVOLUS, INC. research and development in process for the quarter ending 2022-03-31 was $0.00.
- EVOLUS, INC. research and development in process for fiscal 2022 was $2.00M.
- EVOLUS, INC. research and development in process for fiscal 2021 was $0.00.
| Period end | Research and Development in Process | Research and Development in Process 1 month | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $2.00M derived: sum of 3 quarters · filed 2023-03-08 | $2.00M 10-K · filed 2023-03-08 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $2.00M derived: sum of 2 quarters · filed 2022-11-08 | $2.00M 10-Q · filed 2022-11-08 | $2.00M derived: sum of 4 quarters · filed 2023-03-08 | ||
| 2022-06-30 | $2.00M 10-K · filed 2023-03-08 | $2.00M 10-Q · filed 2022-08-02 | $2.00M 10-Q · filed 2022-08-02 | $2.00M derived: sum of 3 quarters · filed 2023-03-08 | $2.00M derived: sum of 4 quarters · filed 2023-03-08 | |
| 2022-06-01 | $2.00M 10-Q · filed 2022-08-02 | |||||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 derived: sum of 4 quarters · filed 2023-03-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | $0.00 10-Q · filed 2022-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |